Stephens Inc. AR Maintains Stake in ZIOPHARM Oncology Inc (ZIOP)
Stephens Inc. AR maintained its position in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 39,108 shares of the biotechnology company’s stock at the close of the 2nd quarter. Stephens Inc. AR’s holdings in ZIOPHARM Oncology were worth $243,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board acquired a new stake in shares of ZIOPHARM Oncology in the 2nd quarter valued at approximately $1,010,000. Vident Investment Advisory LLC boosted its holdings in shares of ZIOPHARM Oncology by 20.0% in the 1st quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock valued at $875,000 after buying an additional 22,996 shares during the last quarter. Old West Investment Management LLC acquired a new stake in shares of ZIOPHARM Oncology in the 1st quarter valued at approximately $205,000. Morgan Stanley boosted its holdings in shares of ZIOPHARM Oncology by 19.5% in the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after buying an additional 324,774 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in shares of ZIOPHARM Oncology in the 2nd quarter valued at approximately $622,000. 41.94% of the stock is owned by institutional investors.
Shares of ZIOPHARM Oncology Inc (NASDAQ ZIOP) opened at 6.17 on Friday. ZIOPHARM Oncology Inc has a one year low of $4.84 and a one year high of $7.88. The firm’s 50-day moving average price is $5.85 and its 200 day moving average price is $6.25. The firm’s market cap is $867.70 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the prior year, the firm posted ($1.01) EPS. The firm’s revenue for the quarter was down 5.9% on a year-over-year basis. Analysts predict that ZIOPHARM Oncology Inc will post ($0.56) EPS for the current year.
Several research firms have recently commented on ZIOP. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Friday, September 15th. BidaskClub downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Finally, HC Wainwright set a $10.00 price objective on ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $13.17.
ZIOPHARM Oncology Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.